ERBB2 and breast carcinoma: Human epidermal growth factor receptor 2 (HER2) was first recognized as an oncogene contributing to the pathogenesis of breast cancer and is a well-established therapeutic target for breast and an increasing number of gastrointestinal cancers [91].